AstraZeneca CEO for Russia and Eurasia Irina Panarina said the vaccine cocktail “is one of the most encouraging vaccination schemes.”
Preliminary results of a study on the combined use of the AstraZeneca vaccine and the first dose of Sputnik V demonstrated efficacy against coronavirus infection and absence of side effects in immunized people, reported the Russian Direct Investment Fund (RDIF).
“The intermediate analysis of the data shows high safety indicators for the combined use of drugs, with the absence of side effects as well as cases of coronavirus infection after vaccination,” said a statement from the RDIF reported today by the agency of Sputnik news.
The text noted that “in August 2021 RDIF and its partners will publish the first data on the immunogenicity of the combined use of the AstraZeneca vaccine and the first component of the Sputnik V vaccine in Azerbaijan.”
Safety and immunogenicity studies, that is, the ability of the drug to trigger an immune response, began in Azerbaijan last February, where 50 people were vaccinated although the admission of volunteers continues.
The RDIF stressed that the clinical study of the vaccine combination is carried out within the framework of a global program that also covers the Arab Emirates, where volunteers have already been immunized, as well as Russia and Belarus, countries in which it was authorized by local regulators but trials have not yet begun.
The studies began in Azerbaijan last February, where 50 people were vaccinated although the admission of volunteers continues”
“In conditions of the emergence of new variants of coronavirus, the cooperation of vaccine producers and the combination of different immunizers plays a crucial role in achieving success in the fight against the pandemic,” said the head of the RDIF, Kiril Dmtriev, quoted in the notice.
He also explained that “based on the high efficacy of the heterogeneous stimulus or cocktail of vaccines, RDIF was the first in the world to make a proposal for cooperation with other producers of anticovid vaccines.”
“The first collaboration of this type was joint clinical trials with the AstraZeneca company,” he added.
Last December, the RDIF together with the Center for Epidemiology and Microbiology Nikoli Gamaleya, developer of the Sputnik V vaccine, and the R-Farm group of companies signed a memorandum of cooperation with AstraZeneca for the development of vaccines against coronavirus.
R-Farm CEO Vasili Igntiev stressed the importance of the fact that the first test results were obtained at the time of the spread of the Delta variant., originated in India and is characterized by being more transmissible.
Meanwhile, the general director of AstraZeneca in Russia and Eurasia, Irina Panarina, affirmed that the vaccine cocktail “is one of the most encouraging vaccination schemes.”